Arpida cuts jobs after US iclaprim setback
This article was originally published in Scrip
Arpidais to cut 60 employees in a restructuring initiative after the US FDAgave a negative recommendation for its extended-spectrum antibiotic iclaprim, for the treatment of severe skin and skin structure infections (Scrip Online, November 21st, 2008). Arpida was surprised and upset by the decision and remained convinced that iclaprim offered a valuable therapeutic asset for the treatment of complicated skin and skin structure infections, especially involving meticillin-resistant Staphylococcus aureus, the company said. It will continue to work with regulatory authorities in the US, Canada and Europe to obtain marketing authorisation and company expects to tell employees of its final decision regarding the restructuring on December 16th.